RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/37391485http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/37391485http://www.w3.org/2000/01/rdf-schema#comment"Many inherited bone marrow failure syndromes (IBMFSs) present a high risk of transformation to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). During transformation of IBMFSs, hematopoietic stem and progenitor cells (HSPCs) with poor fitness gain ectopic, dysregulated self-renewal secondary to somatic mutations via undefined mechanisms. Here, in the context of the prototypical IBMFS Fanconi anemia (FA), we performed multiplexed gene editing of mutational hotspots in MDS-associated genes in human induced pluripotent stem cells (iPSCs) followed by hematopoietic differentiation. We observed aberrant self-renewal and impaired differentiation of HSPCs with enrichment of RUNX1 insertions and deletions (indels), generating a model of IBMFS-associated MDS. We observed that compared to the failure state, FA MDS cells show mutant RUNX1-mediated blunting of the G1/S cell cycle checkpoint that is normally activated in FA in response to DNA damage. RUNX1 indels also lead to activation of innate immune signaling, which stabilizes the homologous recombination (HR) effector BRCA1, and this pathway can be targeted to abrogate viability and restore sensitivity to genotoxins in FA MDS. Together, these studies develop a paradigm for modeling clonal evolution in IBMFSs, provide basic understanding of the pathogenesis of MDS, and uncover a therapeutic target in FA-associated MDS."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.org/dc/terms/identifier"doi:10.1038/s41375-023-01945-6"xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Bauer D.E."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Wang D."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Chen C.C."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Boettcher S."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Peters M."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Shimamura A."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Ebert B.L."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Schlaeger T."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Rowe R.G."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Wells S.I."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Chihanga T."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"da Rocha E.L."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Frenis K."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Ruiz-Torres S."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Marion W."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Starczynowski D."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Aumais O."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Fierstein S."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Koppe T."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/author"Sensharma P."xsd:string
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/date"2023"xsd:gYear
http://purl.uniprot.org/citations/37391485http://purl.uniprot.org/core/name"Leukemia"xsd:string